ResearchMoz

Afatinib (Breast Cancer) - Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 45


GlobalDatas pharmaceuticals report, Afatinib (Breast Cancer) - Analysis and Forecasts to 2020 provides Afatinib sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Afatinib including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Afatinib including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2017-2020 for Afatinib in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Afatinib, Breast cancer, Sales forecast, Phase III, Phase 3, Tyrosine Kinase Inhibitor (HER2, EGFR inhibitor), Competitors to Neratinib, Afinitor and Taxotere, Boehringer Ingelheim, Targeted therapy, Breast cancer, pipeline
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Hormone Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8

3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 Breast Cancer: Most Frequent Cancer in Women 10
3.3.2 Increasing Breast Cancer Incidence Rate 10
3.3.3 Decreasing Breast Cancer Mortality Rate 12
3.3.4 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 17

6 Treatment Options of Breast Cancer 19

6.1 Stage 0 Breast Cancer 19
6.2 Early Stage Breast Cancer (Excluding Stage 0) 20
6.3 Metastatic Breast Cancer (MBC) 22
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line 22
6.3.2 Cytotoxic Chemotherapy 24
6.3.3 Management of Patients with HER-2 Positive Patients 26

7 Afatinib 28
7.1 Introduction 28
7.2 Mechanism of Action 28
7.3 Clinical Studies 28
7.3.1 Phase III trial 28
7.3.2 Phase II trial 28
7.4 Factors Affecting Sales of Afatinib 29
7.4.1 Helps increasing Progression Free Survival 29
7.4.2 Less Toxicity 29
7.4.3 Benefit to Herceptin-Refractory Breast Cancer 29
7.5 Drug Evaluation 30
7.5.1 Drug Risk Benefit Score 30
7.5.2 Intensity of Competition 31
7.6 Sales Forecasts 32
7.6.1 Target Patient Pool of Afatinib 32
7.6.2 Dosing 32
7.6.3 Market Penetration 32
7.6.4 Annual Cost of Therapy 33
7.6.5 Sales Forecasts of Afatinib 33

8 Appendix 42
8.1 Market Definitions 42
8.2 Abbreviations 42
8.3 Research Methodology 42
8.3.1 Coverage 42
8.3.2 Secondary Research 43
8.3.3 Forecasting 43
8.3.4 Number of Patients Approved to Take the Drug 43
8.3.5 Net Penetration of Drug 43
8.3.6 Net Annual Dosing 44
8.3.7 Annual Cost of Therapy 44
8.4 Drug Sales Estimates Model 44
8.5 Contact Us 44
8.6 Disclaimer 44
8.7 Sources 45

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14
Table 3: Drug Risk Benefit Score 30
Table 4: Afatinib, Breast Cancer, Global, Sales Forecasts ($m), 2017–2020 33
Table 5: Afatinib, Breast Cancer, The US, Sales Forecasts ($m), 2017–2020 34
Table 6: Afatinib, Breast Cancer, The UK, Sales Forecasts ($m), 2017–2020 35
Table 7: Afatinib, Breast Cancer, France, Sales Forecasts ($m), 2017–2020 36
Table 8: Afatinib, Breast Cancer, Germany, Sales Forecasts ($m), 2017–2020 37
Table 9: Afatinib, Breast Cancer, Italy, Sales Forecasts ($m), 2017–2020 38
Table 10: Afatinib, Breast Cancer, Spain Sales Forecasts ($m), 2017–2020 39
Table 11: Afatinib, Breast Cancer, Japan, Sales Forecasts ($m), 2017–2020 40

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 18
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 17: Treatment Options, DCIS Breast Cancer 19
Figure 18: Treatment Options, LCIS Breast Cancer 20
Figure 19: Classification of Stages I, II and IIIA 20
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 27: Drug Model Diagram of Afatinib 32
Figure 28: Afatinib, Breast Cancer, Global, Sales Forecasts ($m), 20172020 33
Figure 29: Afatinib, Breast Cancer, The US, Sales Forecasts ($m), 20172020 34
Figure 30: Afatinib, Breast Cancer, The UK, Sales Forecasts ($m), 20172020 35
Figure 31: Afatinib, Breast Cancer, France, Sales Forecasts ($m), 20172020 36
Figure 32: Afatinib, Breast Cancer, Germany, Sales Forecasts ($m), 20172020 37
Figure 33: Afatinib, Breast Cancer, Italy, Sales Forecasts ($m), 20172020 38
Figure 34: Afatinib, Breast Cancer, Spain, Sales Forecasts ($m), 20172020 39
Figure 35: Afatinib, Breast Cancer, Japan, Sales Forecasts ($m), 20172020 40
Figure 36: Afatinib, Breast Cancer, Global, Sales Distribution by Country (%), 2020 41
Figure 37: Patients Approved for the Drug 43

Upcoming Reports:

Greece: fertilizers market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the fertilizers market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the fertilizers market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the...
Poland: ethylene market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the ethylene market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the ethylene market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...
Greece: market of iron or steel domestic appliances
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the iron or steel domestic appliances market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the iron or steel domestic appliances market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com
Select License type:

Share this report

Related News

Loss recorded due to heavy investments carried out by Amazon
Jul 25, 2014  
Amazon.com Inc has been investing in newer businesses like consumer electronics and digital content, due to which it has been running into losses for some time now. The loss recorded in the second quarter was by far the highest. In 2014, the stock prices have dropped by 10% with reduced investor confidence in the long term growth investments. The shares of this US based online retailer...
High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...